{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:05:44Z","timestamp":1777590344282,"version":"3.51.4"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Infections caused by antibiotic resistant bacteria pose a serious threat to global health, leading to higher medical costs, longer hospital stays, and increased morbidity and mortality. An increasing number of bacteria have been implicated in untreatable infections due to multiple resistance mechanisms. In 2017, the World Health Organization published a list of the most important antibiotic resistant bacteria worldwide, for which there is an urgent need to develop new therapeutic options. In recent years, fortunately, new antibiotics have been approved for the treatment of infections caused by multidrug-resistant bacteria. The purpose of this review is to present the most impactful new antibiotics that are currently available for the treatment of these infections. The discovery of new therapeutic strategies will help to limit the spread of multidrug-resistant bacteria, but careful prescribing, appropriate use and monitoring of resistant strains will be crucial to ensure that they remain effective in the future.<\/jats:p>","DOI":"10.3390\/antibiotics14100997","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:05:06Z","timestamp":1759763106000},"page":"997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-6504","authenticated-orcid":false,"given":"Elisabete","family":"Machado","sequence":"first","affiliation":[{"name":"UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Microbiology, Department of Biological Sciences, REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"RISE-Health, Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"},{"name":"Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"}]},{"given":"Jo\u00e3o Carlos","family":"Sousa","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tim.2013.12.007","article-title":"Overcoming the current deadlock in antibiotic research","volume":"22","author":"Hack","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_4","unstructured":"World Health Organization (WHO) (2017). Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2017.12."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0199121","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kabbara, W.K., Sadek, E., and Mansour, H. (2025). Sulbactam\u2013Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii\u2013Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Can. J. Infect. Dis. Med. Microbiol., 2025.","DOI":"10.1155\/cjid\/2001136"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1093\/cid\/ciad093","article-title":"Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections","volume":"76","author":"Watkins","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam\u2013avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: A Phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC-Antimicrobial Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: First approved cefepime-\u03b2-lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Futur. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e02229-19","DOI":"10.1128\/AAC.02229-19","article-title":"Safety and Pharmacokinetic Characterization of Nacubactam, a Novel \u03b2-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers","volume":"64","author":"Mallalieu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00432-19","DOI":"10.1128\/AAC.00432-19","article-title":"Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","article-title":"Contezolid: First Approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2023-0248","article-title":"Sulbactam\u2013durlobactam: A \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting Acinetobacter baumannii","volume":"19","author":"McLeod","year":"2024","journal-title":"Futur. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vrancianu, C.O., Dobre, E.G., Gheorghe, I., Barbu, I., Cristian, R.E., and Chifiriuc, M.C. (2021). Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040730"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Santajit, S., and Indrawattana, N. (2016). Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/2475067"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37201\/req\/s02.01.2022","article-title":"Resistance to beta-lactams in Gram-negative bacilli: Relevance and potential therapeutic alternatives","volume":"35","year":"2022","journal-title":"Rev. Espanola de Quimioter."},{"key":"ref_18","unstructured":"Morgan, G., Yamano, Y., Tone, K., Kinoshita, M., Sawada, T., and Nagata, T. (2025, August 27). Antimicrobial Resistance: Shionogi Advocates Policy Change to Address the Public Health Threat. Nature Portfolio\u2019s Sponsor Features, Available online: https:\/\/www.nature.com\/articles\/d42473-020-00446-9."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Terreni, M., Taccani, M., and Pregnolato, M. (2021). New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules, 26.","DOI":"10.3390\/molecules26092671"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rocha, D.M.G.C., Viveiros, M., Saraiva, M., and Os\u00f3rio, N.S. (2021). The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem. Genes, 12.","DOI":"10.3390\/genes12122003"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","article-title":"Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes","volume":"4","author":"Cox","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMe1900188","article-title":"Omadacycline\u2014The Newest Tetracycline","volume":"380","author":"Chambers","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: A review","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fang, L., Chen, C., Cui, C., Li, X., Zhang, Y., Liao, X., Sun, J., and Liu, Y. (2020). Emerging High-Level Tigecycline Resistance: Novel Tetracycline Destructases Spread via the Mobile Tet(X). BioEssays, 42.","DOI":"10.1002\/bies.202000014"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/phar.2625","article-title":"Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline","volume":"41","author":"Bidell","year":"2021","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Markley, J.L., and Wencewicz, T.A. (2018). Tetracycline-Inactivating Enzymes. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.01058"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/QCO.0000000000001089","article-title":"Omadacycline for the treatment of skin and soft tissue infections","volume":"38","author":"Vena","year":"2025","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Falzon, D., Zignol, M., Bastard, M., Floyd, K., and Kasaeva, T. (2023). The impact of the COVID-19 pandemic on the global tuberculosis epidemic. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1234785"},{"key":"ref_32","unstructured":"World Health Organization (WHO) (2021). Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis, 27-29 October 2020, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240018662."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.2174\/1381612819666131118203641","article-title":"New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics","volume":"20","author":"North","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","article-title":"Pretomanid for tuberculosis: A systematic review","volume":"28","author":"Gils","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","unstructured":"World Health Organization (WHO) (2023). Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240094000."},{"key":"ref_36","first-page":"354","article-title":"Introducing new antibiotics for multidrug-resistant bacteria: Obstacles and the way forward","volume":"31","author":"Carrara","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4155\/fmc-2022-0029","article-title":"Novel Approaches for the Treatment of Infections Due to Multidrug-Resistant Bacterial Pathogens","volume":"14","author":"Imran","year":"2022","journal-title":"Futur. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Abdelrahman, F., Easwaran, M., Daramola, O.I., Ragab, S., Lynch, S., Oduselu, T.J., Khan, F.M., Ayobami, A., Adnan, F., and Torrents, E. (2021). Phage-Encoded Endolysins. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020124"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40121-020-00314-5","article-title":"Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies","volume":"9","author":"Giacobbe","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrgastro.2017.17","article-title":"Modifying recurrence of Clostridium difficile infection","volume":"14","author":"Ray","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schuch, R., Cassino, C., and Vila-Farres, X. (2022). Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.841905"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1172\/JCI136577","article-title":"Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis","volume":"130","author":"Fowler","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/cid\/ciae043","article-title":"Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)","volume":"78","author":"Fowler","year":"2024","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:31:34Z","timestamp":1759764694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["antibiotics14100997"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14100997","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,5]]}}}